Cargando…

Evaluation of hormone receptor, human epidermal growth factor receptor-2 and Ki-67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patients

BACKGROUND: We investigated the reliability of core needle biopsy (CNB) in evaluating the status of hormone receptor (HR), human epidermal growth factor receptor (HER)-2, and Ki-67 status, and the effect of neoadjuvant chemotherapy (NAC) on the expression of these immunohistochemical markers. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ge, Wen-kai, Yang, Ben, Zuo, Wen-shu, Zheng, Gang, Dai, Ying-qi, Han, Chao, Yang, Li, Zheng, Mei-zhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448469/ https://www.ncbi.nlm.nih.gov/pubmed/26273337 http://dx.doi.org/10.1111/1759-7714.12133

Ejemplares similares

Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer
por: Ding, Yuqin, et al.
Publicado: (2020)

The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
por: Zhang, Ailin, et al.
Publicado: (2021)

Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients: A retrospective study of 525 patients
por: Wu, Yu-tuan, et al.
Publicado: (2018)

Ki-67 is a prognostic marker for hormone receptor positive tumors
por: Pérez-López, M. E., et al.
Publicado: (2016)

Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study
por: Chen, Yuhai, et al.
Publicado: (2022)

Association of Menopausal Status, Expression of Progesterone Receptor and Ki67 to the Clinical Response to Neoadjuvant Chemotherapy in Luminal Breast Cancer
por: Silva, Leonardo Roberto da, et al.
Publicado: (2019)

Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Kim, Kwan Il, et al.
Publicado: (2014)

Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
por: Chen, Xiaosong, et al.
Publicado: (2015)

Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2− Early Breast Cancer Patients
por: Li, Shuai, et al.
Publicado: (2022)

Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients
por: Tong, Yiwei, et al.
Publicado: (2023)

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
por: Fasching, Peter A, et al.
Publicado: (2011)

Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients
por: Chen, Rui, et al.
Publicado: (2018)

Effects of core needle biopsy and subsequent neoadjuvant chemotherapy on molecular alterations and outcome in breast cancer
por: Xie, Lingmin, et al.
Publicado: (2018)

Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens
por: Tendl-Schulz, Kristina A., et al.
Publicado: (2020)

Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours.
por: Jaros, E., et al.
Publicado: (1992)

Second-harmonic generation directionality is associated with neoadjuvant chemotherapy response in breast cancer core needle biopsies
por: Desa, Danielle E., et al.
Publicado: (2019)

Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?
por: Ingolf, Juhasz-Böss, et al.
Publicado: (2014)

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy
por: Ács, Balázs, et al.
Publicado: (2017)

Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion
por: Wan, Zhi-Bin, et al.
Publicado: (2018)

Immunohistochemical study of epidermal growth factor receptor, human epidermal growth factor receptor 2/neu, p53, and Ki67 in oral squamous cell carcinoma
por: Mohanapure, Neelam Sureshrao, et al.
Publicado: (2022)

Survivin, Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer
por: LIN, QI, et al.
Publicado: (2013)

Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?
por: Choi, Soon Bo, et al.
Publicado: (2022)

Is Endoscopic Ultrasound-Fine Needle Aspiration for Ki67 Aspirational Enough?
por: David, Yakira, et al.
Publicado: (2020)

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer
por: Burcombe, Russell, et al.
Publicado: (2006)

Serum follicle-stimulating hormone level is associated with human epidermal growth factor receptor type 2 and Ki67 expression in post-menopausal females with breast cancer
por: ZHOU, JUN, et al.
Publicado: (2013)

Expression of p53, epidermal growth factor receptor, Ki-67 and O(6)-methylguanine-DNA methyltransferase in human gliomas
por: HU, XINHUA, et al.
Publicado: (2013)

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population
por: Wang, Jiayu, et al.
Publicado: (2016)

Diagnostic Accuracy of ki-67 Labeling Index in Endoscopic Ultrasonography-Fine-Needle Aspiration Cytology and Biopsy of Pancreatic Neuroendocrine Neoplasms
por: Pyo, Jung-Soo, et al.
Publicado: (2023)

Evaluation of Ki67 Expression across Distinct Categories of Breast Cancer Specimens: A Population-Based Study of Matched Surgical Specimens, Core Needle Biopsies and Tissue Microarrays
por: Knutsvik, Gøril, et al.
Publicado: (2014)

Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers
por: Srivastava, Pooja, et al.
Publicado: (2022)

The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy
por: Elmahs, Aya, et al.
Publicado: (2022)

Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies
por: Romero, Quinci, et al.
Publicado: (2011)

Needle core biopsy for breast lesions: An audit of 467 needle core biopsies
por: Radhakrishna, Selvi, et al.
Publicado: (2013)

Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma
por: Rossi, L, et al.
Publicado: (2015)

A Novel Model Incorporating Tumor Stiffness, Blood Flow Characteristics, and Ki-67 Expression to Predict Responses After Neoadjuvant Chemotherapy in Breast Cancer
por: Zhang, Jing, et al.
Publicado: (2020)

Meta-Analysis of Shrinkage Mode After Neoadjuvant Chemotherapy for Breast Cancers: Association With Hormonal Receptor
por: Zheng, Chun-Hui, et al.
Publicado: (2022)

Magnetic Resonance Metabolic Profiling of Breast Cancer Tissue Obtained with Core Needle Biopsy for Predicting Pathologic Response to Neoadjuvant Chemotherapy
por: Choi, Ji Soo, et al.
Publicado: (2013)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
por: Wang, Ruo-Xi, et al.
Publicado: (2016)

Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014
por: Moazed, Vahid, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ungo706h2v8hln0tegthni872q